Morfina Cloridrato Molteni (Morphine Hydrochloride)

Morphine binds to μ‑opioid receptors in the brain, spinal cord, and peripheral nervous system. This binding activates inhibitory G‑proteins, reducing calcium influx and increasing potassium efflux, which suppresses the release of pain‑transmitting neurotransmitters and diminishes neuronal excitability, resulting in analgesia.

The appropriate dose is individualized by the prescribing clinician based on the patient’s pain intensity, prior opioid exposure, age, weight, organ function, and concurrent medications. Dosage adjustments are made to achieve adequate pain control while minimizing adverse effects.

Safety data for morphine in pregnancy and lactation are limited. Opioids can cross the placenta and appear in breast milk, potentially causing neonatal respiratory depression or sedation. Use is generally avoided unless the benefit outweighs the risk, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Morphine and fentanyl are both potent opioids but differ in pharmacokinetics and potency. Morphine has a slower onset and longer duration, making it suitable for continuous infusion or repeated dosing, whereas fentanyl is more lipophilic, has a rapid onset, and is often used for breakthrough pain or anesthesia. Choice depends on clinical context, patient factors, and required analgesic profile.

The product should be stored below 25 °C in its original packaging, protected from light and moisture. Do not freeze the solution. Ensure that storage areas are secure and that the product is kept out of reach of unauthorized personnel.

Morfina Cloridrato Molteni is supplied as a sterile injectable solution. It can be given epidurally for regional analgesia, intramuscularly for rapid systemic effect, or intravenously for immediate pain control. Administration must be performed by qualified healthcare professionals following aseptic technique and appropriate dosing guidelines.

The most critical risks include respiratory depression, which can be fatal if not promptly recognized; severe hypotension; anaphylactic reactions; development of physical dependence and withdrawal syndrome; and rare events such as adrenal insufficiency or seizures. Continuous monitoring of respiratory and cardiovascular status is essential, especially after dose changes.

Morphine is contraindicated in patients with known hypersensitivity to morphine or any opioid, those who have received monoamine oxidase inhibitors within the past 14 days, and individuals with significant respiratory compromise such as severe asthma or untreated obstructive sleep apnea. Caution is also advised for patients with uncontrolled head injury or increased intracranial pressure.